MYD1 Recombinant Protein: Structural Features, Production Technologies, and Advances in Biomedical Applications

MYD1 Recombinant Protein

1. Molecular Structure and Functional Properties of MYD1

MYD1 (Macrophage-Derived 1 protein), a member of the immunoglobulin superfamily, exhibits distinct structural features. Encoded by the SHPS1 gene, MYD1 comprises three functional domains:

• Extracellular domain: Three immunoglobulin-like V-type domains (IgV-IgV-IgC) enabling ligand recognition.
• Transmembrane domain: α-helical structure ensuring membrane localization.
• Intracellular domain: Immunoreceptor tyrosine-based inhibitory motif (ITIM) mediating signal transduction.

Schematic of MYD1 Protein 3D Structure

Functional studies reveal MYD1 regulates cellular activities via dual mechanisms:

• Negative regulation: ITIM domain recruits SHP-1/2 phosphatases upon CD47 binding, inhibiting receptor tyrosine kinase (RTK) signaling.
• Immunomodulation: Suppresses TLR signaling in dendritic cells, reducing pro-inflammatory cytokines (e.g., IL-12).

2. Optimization Strategies for Recombinant Expression Systems
MYD1 recombinant protein production involves multi-faceted technological innovations:

Schematic of Recombinant Protein Purification Workflow

Recent studies show fusion tag strategies (SUMO tag) enhance soluble expression rates to 82%, a 2.3-fold improvement over conventional His-tag systems. Dynamic light scattering (DLS) analysis confirms optimized protein size distribution (PDI < 0.1) meets pharmaceutical standards.

3. Biomedical Application Advances

Breakthroughs in Oncology

MYD1-72 recombinant protein demonstrates significant efficacy in PDAC models:

• Monotherapy reduces tumor volume by 78.4% (vs. control, p < 0.001).
• Synergistic effect with doxorubicin (CI = 0.32).
• Mechanism: Blocks Gas6/Axl signaling axis to inhibit EMT.

Pre- and Post-Treatment Comparison in Pancreatic Cancer Mouse Model

Cardiovascular Applications

In myocardial regeneration studies:

• Promotes cardiomyocyte proliferation (Ki67+ cells increase 5.8-fold).
• Improves ejection fraction (EF) in MI models (32% → 49%).
• Modulates Wnt/β-catenin pathway activation.

Neurodegenerative Diseases

Alzheimer's disease models show:

• Reduced Aβ plaque deposition (38.7% ↓).
• Improved spatial memory (Morris water maze latency reduced by 56 seconds).

4. Technical Challenges and Innovative Directions

Current bottlenecks include:

• Protein aggregation during scale-up (≥10 mg/mL forms dimers).
• Absence of glycosylation affecting in vivo half-life.
• Inefficient transmembrane domain refolding (<40%).

Cutting-edge technologies under exploration:

• AI-assisted design: AlphaFold2 predicts mutation sites (D128K mutation enhances stability).
• Microfluidics: Nanoliter-scale condition screening (50-fold efficiency improvement).
• Site-specific conjugation: PEGylation extends circulation time (t1/2 from 4 h to 28 h).

5. Clinical Translation Progress

As of 2025, six global clinical trials are underway:

Safety data shows a 6.7% incidence of ≥Grade 3 AEs in Phase II trials, primarily transient fever (CTCAE Grade 1).

6. Future Trends

• Multi-omics integration: Single-cell sequencing reveals subpopulation response heterogeneity.
• Smart delivery systems: Lipid nanoparticle targeting efficiency exceeds 75%.
• Synthetic biology: Light-controllable MYD1 variants (LOV2 domain fusion).
• Global R&D landscape: Three major clusters in US, EU, and China; patent applications grow 29% annually.

Conclusion

MYD1 recombinant protein research is at a pivotal stage of clinical translation. With advancements in structural biology, computational modeling, and nanotechnology, its therapeutic potential will be fully unlocked. The first MYD1-based biologic is projected to complete Phase III trials within five years, offering novel treatment options for oncology, cardiovascular diseases, and beyond.